Author + information
- Received April 15, 2011
- Revision received August 2, 2011
- Accepted August 2, 2011
- Published online November 15, 2011.
- Benoit Daneault, MD,
- Ajay J. Kirtane, MD, SM,
- Susheel K. Kodali, MD,
- Mathew R. Williams, MD,
- Philippe Genereux, MD,
- George R. Reiss, MD,
- Craig R. Smith, MD,
- Jeffrey W. Moses, MD and
- Martin B. Leon, MD⁎ ()
- ↵⁎Reprint requests and correspondence
: Dr. Martin B. Leon, Columbia University Medical Center, New York-Presbyterian Hospital, 177 Fort Washington Avenue, New York, New York 10032
Stroke is a potential complication of treating patients with aortic stenosis via surgical aortic valve replacement (AVR), transcatheter aortic valve replacement (TAVR), and balloon aortic valvuloplasty. Because there are limited and heterogeneous data on the incidence, risk factors, and outcomes of stroke among patients being treated for aortic stenosis, we performed a comprehensive review of the literature. The risk of stroke after AVR in the general population is approximately 1.5%, and the risk is increased (to approximately 2% to 4%) in older and higher-risk patients. Strokes were reported in 1.5% to 6% of patients treated with TAVR, and in the only randomized trial of AVR versus TAVR, there was an increased risk of 30-day strokes (minor and major strokes and transient ischemic attacks) with TAVR (5.5% vs. 2.4%, p = 0.04).
- aortic stenosis
- aortic valve replacement
- aortic valvuloplasty
- transcatheter aortic valve replacement
Dr. Daneault has received consultant fees from Edwards Lifesciences. Dr. Kodali is a consultant for St. Jude Medical and Medtronic; and a consultant/case proctor for Edwards LifeSciences. Dr. Williams has received consultant fees from Edwards LifeSciences. Dr. Genereux has received speaking honoraria and consulting fees from Edwards Lifesciences. Dr. Smith is a nonpaid member of the Scientific Advisory Board of Edwards Lifesciences. Dr. Moses has equity in Claret Medical. Dr. Leon is a nonpaid member of the Scientific Advisory Board of Edwards Lifesciences and Medtronic Vascular. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received April 15, 2011.
- Revision received August 2, 2011.
- Accepted August 2, 2011.
- American College of Cardiology Foundation
- Potential Sources of Embolization
- Stroke in Surgical AVR Patients
- Stroke and TAVR
- Difficulties in Interpreting Stroke Data Across AVR and TAVR Studies
- Randomized Trials of TAVR
- Stroke and BAV
- Neuroimaging After AVR and TAVR
- Risk Factors for Post-Procedure Stroke
- Timing of Stroke After Procedures
- Outcomes After Stroke